Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Bank of America

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Bank of America from an “underperform” rating to a “buy” rating in a report issued on Wednesday, Marketbeat Ratings reports. The firm currently has a $860.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $627.00. Bank of America‘s price target suggests a potential upside of 7.36% from the stock’s previous close.

REGN has been the topic of several other reports. Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. Royal Bank Of Canada increased their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 29th. Finally, Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $791.05.

Regeneron Pharmaceuticals Stock Down 1.4%

Shares of NASDAQ REGN opened at $801.01 on Wednesday. The company has a 50 day simple moving average of $735.23 and a 200 day simple moving average of $626.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $816.99. The firm has a market cap of $84.19 billion, a PE ratio of 19.18, a price-to-earnings-growth ratio of 2.42 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the previous year, the firm posted $12.46 EPS. On average, research analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 8,431 shares of company stock valued at $5,733,521. Company insiders own 7.02% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Marino Stram & Associates LLC raised its holdings in shares of Regeneron Pharmaceuticals by 5.3% in the second quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 20 shares during the last quarter. CoreCap Advisors LLC grew its position in Regeneron Pharmaceuticals by 9.2% in the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock worth $134,000 after purchasing an additional 20 shares in the last quarter. Strait & Sound Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 3.5% in the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $353,000 after buying an additional 21 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Regeneron Pharmaceuticals by 14.8% during the 3rd quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock worth $92,000 after buying an additional 21 shares in the last quarter. Finally, MAI Capital Management lifted its position in shares of Regeneron Pharmaceuticals by 2.1% during the 3rd quarter. MAI Capital Management now owns 1,028 shares of the biopharmaceutical company’s stock worth $578,000 after buying an additional 21 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America upgraded REGN from Underperform to Buy and lifted its price target to $860, citing improving fundamentals and 2026 catalysts, a clear bullish catalyst for the stock. Regeneron Pharmaceuticals upgraded by Bank of America
• Positive Sentiment: Truist raised its price target to $820 and reiterated a Buy, adding incremental upside and supporting analyst-driven demand. Truist raises price target
• Positive Sentiment: Aggregated analyst coverage is shifting more positive (multiple upgrade pieces and a roundup of 21 analyst views), which can drive buy-side interest and shorten-term momentum. 21 analysts assess Regeneron
• Neutral Sentiment: Unusual options activity has been reported, indicating increased speculative positioning and hedging that can amplify intraday moves but is ambiguous for longer-term direction. Unusual options activity
• Neutral Sentiment: Coverage pieces note falling short interest and renewed bullish cases; lower short interest reduces short-squeeze potential but supports steadier upside if fundamentals hold. Analyst upgrades and short-interest drop
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at ~$800 on Jan. 7, which can be viewed by some investors as a signal to take profits. Director share sale disclosed

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.